Treatment of Parkinson's Disease with Ropinirole after Pergolide-Induced Retroperitoneal Fibrosis
โ Scribed by Dr. Brian C. Lund; Dr. Richard F. Neiman; Dr. Paul J. Perry
- Book ID
- 115047654
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 22 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0277-0008
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn
## Abstract The aims of this study were to assess the safety, tolerability, and efficacy of sumanirole, a highly selective D~2~ dopamine receptor agonist, versus placebo in subjects with advanced Parkinson's disease (PD), and to demonstrate noninferiority of sumanirole to ropinirole. In this flexib
## Abstract To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo.